Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.
Allogeneic haematopoietic stem cell transplantation
MSC-FFM
Mesenchymal stromal cells
Ruxolitinib-refractory
Steroid-refractory
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
07
09
2023
accepted:
13
11
2023
medline:
23
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Patients with steroid-refractory acute graft-versus-host disease (aGvHD) not tolerating/responding to ruxolitinib (RR-aGvHD) have a dismal prognosis. We retrospectively assessed real-world outcomes of RR-aGvHD treated with the random-donor allogeneic MSC preparation MSC-FFM, available via Hospital Exemption in Germany. MSC-FFM is provided as frozen cell dispersion for administration as i.v. infusion immediately after thawing, at a recommended dose of 1-2 million MSCs/kg body weight in 4 once-weekly doses. 156 patients, 33 thereof children, received MSC-FFM; 5% had Grade II, 40% had Grade III, and 54% had Grade IV aGvHD. Median (range) number of prior therapies was 4 (1-10) in adults and 7 (2-11) in children. The safety profile of MSC-FFM was consistent with previous reports for MSC therapies in general and MSC-FFM specifically. The overall response rate at Day 28 was 46% (95% confidence interval [CI] 36-55%) in adults and 64% (45-80%) in children; most responses were durable. Probability of overall survival at 6, 12 and 24 months was 47% (38-56%), 35% (27-44%) and 30% (22-39%) for adults, and 59% (40-74%), 42% (24-58%) and 35% (19-53%) for children, respectively (whole cohort: median OS 5.8 months). A recent real-world analysis of outcomes for 64 adult RR-aGvHD patients not treated with MSCs reports survival of 20%, 16% and 10% beyond 6, 12 and 24 months, respectively (median 28 days). Our data thus suggest effectiveness of MSC-FFM in RR-aGvHD.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with steroid-refractory acute graft-versus-host disease (aGvHD) not tolerating/responding to ruxolitinib (RR-aGvHD) have a dismal prognosis.
METHODS
METHODS
We retrospectively assessed real-world outcomes of RR-aGvHD treated with the random-donor allogeneic MSC preparation MSC-FFM, available via Hospital Exemption in Germany. MSC-FFM is provided as frozen cell dispersion for administration as i.v. infusion immediately after thawing, at a recommended dose of 1-2 million MSCs/kg body weight in 4 once-weekly doses. 156 patients, 33 thereof children, received MSC-FFM; 5% had Grade II, 40% had Grade III, and 54% had Grade IV aGvHD. Median (range) number of prior therapies was 4 (1-10) in adults and 7 (2-11) in children.
RESULTS
RESULTS
The safety profile of MSC-FFM was consistent with previous reports for MSC therapies in general and MSC-FFM specifically. The overall response rate at Day 28 was 46% (95% confidence interval [CI] 36-55%) in adults and 64% (45-80%) in children; most responses were durable. Probability of overall survival at 6, 12 and 24 months was 47% (38-56%), 35% (27-44%) and 30% (22-39%) for adults, and 59% (40-74%), 42% (24-58%) and 35% (19-53%) for children, respectively (whole cohort: median OS 5.8 months).
CONCLUSION
CONCLUSIONS
A recent real-world analysis of outcomes for 64 adult RR-aGvHD patients not treated with MSCs reports survival of 20%, 16% and 10% beyond 6, 12 and 24 months, respectively (median 28 days). Our data thus suggest effectiveness of MSC-FFM in RR-aGvHD.
Identifiants
pubmed: 37990219
doi: 10.1186/s12967-023-04731-1
pii: 10.1186/s12967-023-04731-1
pmc: PMC10664468
doi:
Substances chimiques
ruxolitinib
82S8X8XX8H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
837Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694
pubmed: 30965140
Biol Blood Marrow Transplant. 2017 Jul;23(7):1122-1127
pubmed: 28344057
Biol Blood Marrow Transplant. 2020 May;26(5):835-844
pubmed: 31505228
Blood. 2020 May 14;135(20):1739-1749
pubmed: 32160294
Pediatr Blood Cancer. 2020 Sep;67(9):e28233
pubmed: 32614145
Lancet. 2004 May 1;363(9419):1439-41
pubmed: 15121408
Bone Marrow Transplant. 2020 Jun;55(6):1041-1049
pubmed: 31822813
Haematologica. 2022 May 01;107(5):1054-1063
pubmed: 34162176
Elife. 2022 Jul 15;11:
pubmed: 35838024
J Transl Med. 2019 Nov 29;17(1):397
pubmed: 31783866
Biol Blood Marrow Transplant. 2011 Apr;17(4):534-41
pubmed: 20457269
Cells. 2019 Dec 05;8(12):
pubmed: 31817480
Cochrane Database Syst Rev. 2019 Jan 30;1:CD009768
pubmed: 30697701
Bone Marrow Transplant. 2018 Jul;53(7):852-862
pubmed: 29379171
Lancet Haematol. 2016 Jan;3(1):e45-52
pubmed: 26765648
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):642-647
pubmed: 34889409
N Engl J Med. 2020 May 7;382(19):1800-1810
pubmed: 32320566
Adv Hematol. 2011;2011:601953
pubmed: 22110505
Transfus Med Hemother. 2019 Feb;46(1):27-34
pubmed: 31244579
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63
pubmed: 22510384
Bone Marrow Transplant. 2021 Oct;56(10):2355-2366
pubmed: 33976381
Lancet. 2008 May 10;371(9624):1579-86
pubmed: 18468541
Biol Blood Marrow Transplant. 2002;8(7):387-94
pubmed: 12171485
Front Immunol. 2022 Aug 04;13:954268
pubmed: 35990629
Leuk Res. 2023 Feb;125:107005
pubmed: 36580876
Blood. 2020 Oct 22;136(17):1903-1906
pubmed: 32756949
Stem Cells Transl Med. 2018 Apr;7(4):325-331
pubmed: 29533533
Drug Des Devel Ther. 2021 Feb 22;15:743-752
pubmed: 33654380
Stem Cells Dev. 2015 Oct 1;24(19):2269-79
pubmed: 26192403
Br J Haematol. 2021 Nov;195(3):429-432
pubmed: 34254289
Lancet Haematol. 2020 Feb;7(2):e157-e167
pubmed: 32004485
Haematologica. 2016 Aug;101(8):985-94
pubmed: 27175026